CD137

From Wikipedia, the free encyclopedia
Jump to: navigation, search
TNFRSF9
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases TNFRSF9, 4-1BB, CD137, CDw137, ILA, tumor necrosis factor receptor superfamily member 9
External IDs OMIM: 602250 MGI: 1101059 HomoloGene: 1199 GeneCards: 3604
RNA expression pattern
PBB GE TNFRSF9 207536 s at tn.png

PBB GE TNFRSF9 211786 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001561

NM_001077508
NM_001077509
NM_011612

RefSeq (protein)

NP_001552.2

NP_001070977.1
NP_035742.1

Location (UCSC) Chr 1: 7.92 – 7.94 Mb Chr 4: 150.91 – 150.95 Mb
PubMed search [1] [2]
Wikidata
View/Edit Human View/Edit Mouse

CD137 is a member of the tumor necrosis factor (TNF) receptor family. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB and induced by lymphocyte activation (ILA). It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule.

Expression[edit]

CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation.

Specific effects on cells[edit]

The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion, survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice.

Interactions[edit]

CD137 has been shown to interact with TRAF2.[1][2]

As a drug target[edit]

Utomilumab[edit]

Utomilumab (PF-05082566) targets this antibody to stimulate a more intense immune system attack on cancers.[3] It is a fully human IgG2 monoclonal antibody.[4] It is in early clinical trials.[3] As of June 2016 5 clinical trials are active.[5]

See also[edit]

References[edit]

Further reading[edit]